cyclophosphamide + methotrexate + vincristine + prednisone

This is a multi-agent chemotherapy regimen composed of four drugs—cyclophosphamide, methotrexate, vincristine, and prednisone. Each component has a distinct mechanism of action: - Cyclophosphamide is an alkylating agent that crosslinks DNA strands, inhibiting DNA replication and leading to cell death. - Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking folic acid metabolism and thus DNA synthesis. - Vincristine is a vinca alkaloid that disrupts microtubule formation in mitosis, arresting cell division at metaphase. - Prednisone is a synthetic glucocorticoid with lympholytic effects; it induces apoptosis in certain cancer cells. This combination targets rapidly dividing malignant cells through multiple mechanisms. It has been used as part of various protocols for hematologic malignancies such as acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), T-cell lymphomas, and other related cancers[1][5][6]. The specific regimen may vary by disease subtype and treatment protocol.

Other names

环磷酰胺 + 甲氨蝶呤 + 长春新碱 + 泼尼松